Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash & Equivalents data on record, last reported at $260.8 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 24.8% to $260.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $260.8 million, a 24.8% decrease, with the full-year FY2025 number at $174.0 million, down 55.15% from a year prior.
  • Cash & Equivalents reached $260.8 million in Q1 2026 per PCVX's latest filing, up from $174.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PCVX hit a ceiling of $1.1 billion in Q3 2024 and a floor of $174.0 million in Q4 2025.
  • A 5-year average of $432.0 million and a median of $380.5 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1109.91% in 2022, then plummeted 73.24% in 2025.
  • Tracing PCVX's Cash & Equivalents over 5 years: stood at $834.7 million in 2022, then crashed by 52.38% to $397.5 million in 2023, then fell by 2.41% to $387.9 million in 2024, then tumbled by 55.15% to $174.0 million in 2025, then soared by 49.95% to $260.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for PCVX at $260.8 million in Q1 2026, $174.0 million in Q4 2025, and $281.1 million in Q3 2025.